Chasing Life Beyond the Headlines of MAHA With the FDA
8 snips
Oct 3, 2025 
Dr. Marty Makary, a surgical oncologist and U.S. FDA Commissioner, joins Dr. Sanjay Gupta to explore crucial FDA initiatives. They discuss plans for FDA modernization, aiming to expedite drug approvals without compromising safety. The conversation highlights efforts to eliminate harmful food ingredients for children's health and the importance of addressing the potential link between prenatal acetaminophen and neurodevelopmental disorders. Makary emphasizes the role of big data in ongoing monitoring of drug safety, aiming to build public trust in FDA processes.
AI Snips
Chapters
Transcript
Episode notes
Modernize FDA To Cut Idle Time
- Marty Makary plans to modernize FDA processes to cut idle time and speed decisions without lowering safety standards.
- He proposes continuous trials and centralized reviews to produce decisions in weeks rather than years.
Small Food Changes Aim Big Health Gains
- The FDA is targeting food chemicals to address childhood health, replacing petroleum-based dyes with natural alternatives.
- Makary argues small ingredient changes can shift industry behavior and improve child health over time.
Last Operation Before FDA Role
- Makary stopped operating the day before his Senate confirmation and said that might've been his last surgery.
- He described transitioning from individual patient care to leading a public health agency.